Background

Cardiovascular diseases are the most common cause of death in the western world today and currently there are no effective artificial revascularisation treatments for vessels with an internal diameter below five millimetres. It is Arterion's aim to find a solution.

Further reading about our bacterial cellulose and medical device development can be found here.

The research behind Arterion's technology initially started as a PhD project at the Biopolymer Department of Chalmers University of Technology in 2000. Once the potential in microbially derived cellulose as a biomaterial became evident our research then focused towards artificial blood vessels.

A collaboration between Chalmers and the Vascular Engineering Center at Göteborg University and Sahlgrenska University Hospital was formed in 2003 and then the clinical potential was examined.

In 2006 the commercial potential was fully investigated and the research project entered the Göteborg International Bioscience Business School (GIBBS).